Identify health risks early

You know your patients and their families better than most doctors. But family history alone isn’t enough to determine her risk of cancer and cardiovascular disease. Offering genetic testing to all women helps you identify those who need additional care.¹
Two women's faces
Middle aged dark haired yellow shirt female back profile in circular shape

Cancer screening can help you see who’s at increased risk of hereditary cancer before you find a lump

Offering comprehensive hereditary cancer screening to all women may be key to catching cancer early or preventing it altogether.¹,²

  • Nearly half of patients with a BRCA1 or BRCA2 genetic variant do not have a suggestive family history—but need additional care
  • Offering hereditary cancer screening to every woman in their annual exam can close the gap
Black female with partial smile

You can give women at elevated risk of developing cancer a better chance at living longer

Early identification leads to improved outcomes. For patients with BRCA1 or BRCA2 variants, knowing their genetic status before a breast cancer diagnosis leads to improved survival rates.³

ACOG/AHA joint advisory:

The annual well-woman visit provides a powerful opportunity to counsel patients about minimizing their future cardiovascular health risks.⁴

5-year survival rates improve when patients know their BRCA status

The 5-year survival rate in patients who knew their BRCA1/BRCA2 status before diagnosis is 94% compared with 78% in patients who only found out their status after diagnosis (P<0.03).3

78

%

Status unknown at diagnosis

94

%

Status unknown before diagnosis

See tests
Patient stories - ob and onc journey pages carousel, click to skip carousel
9 in 10 women are at risk infographic

When you think about her future risk, don’t forget her heart

Many women see their Ob/Gyn as their primary healthcare provider, particularly during childbearing years. You have a unique opportunity to assess early cardiovascular risk in your patients with genetic testing.⁴

Heart disease is the #1 cause of death in women, yet it remains underdiagnosed and undertreated. Heart disease risk rises during pregnancy and after menopause.⁵⁻⁷

  • 90% of women have at least 1 risk factor for developing heart disease⁴
  • Women are less likely to receive cardiovascular diagnostic tests than men—and are 50% more likely to be initially misdiagnosed⁷,
Female with hair wrap in shape

Knowing what her genes say about future heart problems is the first step to preventing them

Hereditary cardiovascular diseases are some of the most common genetic disorders, affecting more than 1 in 200 people.⁹ Optimal prevention strategies begin decades before clinical heart disease appears.⁴ That’s one reason the American Heart Association recommends genetic screening as part of a cardiovascular risk assessment.¹⁰
77% would test piechart infographic

77% of people

would take a test if it helped them develop a personalized health plan¹¹

Test today for their tomorrow

Create an account

ACOG=American College of Obstetrics and Gynecology
AHA=American Heart Association

References

1. Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7(2):230–237. doi:10.1001/jamaoncol.2020.6252.
2. ACOG Committee Opinion No. 793: Hereditary cancer syndromes and risk assessment. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2019;134(6):e143-e149.
3. Hadar T, Mor P, Amit G, et al. Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer. Letter. JAMA Oncol. 2020;6(9):1460-1463. doi:10.1001/jamaoncol.2020.2059.
4. Brown HL, Warner JJ, Gianos E, et al. On behalf of the American Heart Association and the American College of Obstetricians and Gynecologists. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American College of Obstetricians and Gynecologists. Circulation. 2018;137:e843–e852. doi:10.1161/CIR.0000000000000582.
5. Women and heart disease. Centers for Disease Control and Prevention website. Updated January 31, 2020. Accessed March 24, 2021. https://www.cdc.gov/heartdisease/women.htm.
6. Newson L. Menopause and cardiovascular disease. Post Reprod Health. 2018;24(1):44-49. doi:10.1177/2053369117749675.
7. Shah ASV, Griffiths M, Lee KK, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873. doi:10.1136/bmj.g7873.
8. Alabas OA, Gale CP, et al. Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: National cohort study using the SWEDEHEART Registry. J. Am. Heart Assoc. 2017;6(12):e007123. doi: 10.1161/JAHA.117.007123.
9. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254. doi:10.1016/j.jacc.2015.01.019.
10. Musunuru K, Hershberger RE, Day SM, et al. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2020;13(4):e000067. doi:10.1161/HCG.0000000000000067.
11. U.S. public opinion about personalized medicine. Personalized Medicine Coalition. Accessed April 2020.